Droxidopa for neurogenic orthostatic hypotension

William P. Cheshire

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Neurogenic orthostatic hypotension is a disabling manifestation of autonomic failure seen in disorders such as multiple system atrophy, pure autonomic failure, Lewy body disease, Parkinsons disease, autonomic neuropathies and dopamine β-hydroxylase deficiency.Areas covered: Droxidopa is an orally administered norepinephrine prodrug that was approved in the US in the year 2014 for the treatment of neurogenic orthostatic hypotension. This review examines the published pharmacodynamic, pharmacokinetic, safety and efficacy data including the results of phase II and phase III studies of droxidopa.Expert opinion: Droxidopa has been shown to have measurable clinical benefit in reducing the symptoms of neurogenic orthostatic hypotension, in particular postural lightheadedness despite its modest pressor effect, and it has been well-tolerated. As studies to date have demonstrated only short-term efficacy and safety, longer-term studies are needed to establish the durability of efficacy. An important safety concern is droxidopas potential to exacerbate supine hypertension, which commonly occurs in neurogenic orthostatic hypotension. Direct comparison studies are needed with other treatment approaches for neurogenic orthostatic hypotension.

Original languageEnglish (US)
Pages (from-to)1479-1490
Number of pages12
JournalExpert Opinion on Orphan Drugs
Volume3
Issue number12
DOIs
StatePublished - Dec 2 2015

Fingerprint

Droxidopa
Orthostatic Hypotension
Safety
Pure Autonomic Failure
Multiple System Atrophy
Lewy Body Disease
Prodrugs
Expert Testimony
Dizziness
Mixed Function Oxygenases
Parkinson Disease
Dopamine
Norepinephrine
Pharmacokinetics
Hypertension

Keywords

  • autonomic neuropathy
  • droxidopa
  • L-threo-3-dihydroxyphenylserine
  • multiple system atrophy
  • neurogenic orthostatic hypotension
  • Parkinson's disease
  • supine hypertension

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Droxidopa for neurogenic orthostatic hypotension. / Cheshire, William P.

In: Expert Opinion on Orphan Drugs, Vol. 3, No. 12, 02.12.2015, p. 1479-1490.

Research output: Contribution to journalArticle

Cheshire, William P. / Droxidopa for neurogenic orthostatic hypotension. In: Expert Opinion on Orphan Drugs. 2015 ; Vol. 3, No. 12. pp. 1479-1490.
@article{8c30c59862a6443294651f7445c07c55,
title = "Droxidopa for neurogenic orthostatic hypotension",
abstract = "Introduction: Neurogenic orthostatic hypotension is a disabling manifestation of autonomic failure seen in disorders such as multiple system atrophy, pure autonomic failure, Lewy body disease, Parkinsons disease, autonomic neuropathies and dopamine β-hydroxylase deficiency.Areas covered: Droxidopa is an orally administered norepinephrine prodrug that was approved in the US in the year 2014 for the treatment of neurogenic orthostatic hypotension. This review examines the published pharmacodynamic, pharmacokinetic, safety and efficacy data including the results of phase II and phase III studies of droxidopa.Expert opinion: Droxidopa has been shown to have measurable clinical benefit in reducing the symptoms of neurogenic orthostatic hypotension, in particular postural lightheadedness despite its modest pressor effect, and it has been well-tolerated. As studies to date have demonstrated only short-term efficacy and safety, longer-term studies are needed to establish the durability of efficacy. An important safety concern is droxidopas potential to exacerbate supine hypertension, which commonly occurs in neurogenic orthostatic hypotension. Direct comparison studies are needed with other treatment approaches for neurogenic orthostatic hypotension.",
keywords = "autonomic neuropathy, droxidopa, L-threo-3-dihydroxyphenylserine, multiple system atrophy, neurogenic orthostatic hypotension, Parkinson's disease, supine hypertension",
author = "Cheshire, {William P.}",
year = "2015",
month = "12",
day = "2",
doi = "10.1517/21678707.2015.1113873",
language = "English (US)",
volume = "3",
pages = "1479--1490",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Droxidopa for neurogenic orthostatic hypotension

AU - Cheshire, William P.

PY - 2015/12/2

Y1 - 2015/12/2

N2 - Introduction: Neurogenic orthostatic hypotension is a disabling manifestation of autonomic failure seen in disorders such as multiple system atrophy, pure autonomic failure, Lewy body disease, Parkinsons disease, autonomic neuropathies and dopamine β-hydroxylase deficiency.Areas covered: Droxidopa is an orally administered norepinephrine prodrug that was approved in the US in the year 2014 for the treatment of neurogenic orthostatic hypotension. This review examines the published pharmacodynamic, pharmacokinetic, safety and efficacy data including the results of phase II and phase III studies of droxidopa.Expert opinion: Droxidopa has been shown to have measurable clinical benefit in reducing the symptoms of neurogenic orthostatic hypotension, in particular postural lightheadedness despite its modest pressor effect, and it has been well-tolerated. As studies to date have demonstrated only short-term efficacy and safety, longer-term studies are needed to establish the durability of efficacy. An important safety concern is droxidopas potential to exacerbate supine hypertension, which commonly occurs in neurogenic orthostatic hypotension. Direct comparison studies are needed with other treatment approaches for neurogenic orthostatic hypotension.

AB - Introduction: Neurogenic orthostatic hypotension is a disabling manifestation of autonomic failure seen in disorders such as multiple system atrophy, pure autonomic failure, Lewy body disease, Parkinsons disease, autonomic neuropathies and dopamine β-hydroxylase deficiency.Areas covered: Droxidopa is an orally administered norepinephrine prodrug that was approved in the US in the year 2014 for the treatment of neurogenic orthostatic hypotension. This review examines the published pharmacodynamic, pharmacokinetic, safety and efficacy data including the results of phase II and phase III studies of droxidopa.Expert opinion: Droxidopa has been shown to have measurable clinical benefit in reducing the symptoms of neurogenic orthostatic hypotension, in particular postural lightheadedness despite its modest pressor effect, and it has been well-tolerated. As studies to date have demonstrated only short-term efficacy and safety, longer-term studies are needed to establish the durability of efficacy. An important safety concern is droxidopas potential to exacerbate supine hypertension, which commonly occurs in neurogenic orthostatic hypotension. Direct comparison studies are needed with other treatment approaches for neurogenic orthostatic hypotension.

KW - autonomic neuropathy

KW - droxidopa

KW - L-threo-3-dihydroxyphenylserine

KW - multiple system atrophy

KW - neurogenic orthostatic hypotension

KW - Parkinson's disease

KW - supine hypertension

UR - http://www.scopus.com/inward/record.url?scp=84952873343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952873343&partnerID=8YFLogxK

U2 - 10.1517/21678707.2015.1113873

DO - 10.1517/21678707.2015.1113873

M3 - Article

AN - SCOPUS:84952873343

VL - 3

SP - 1479

EP - 1490

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 12

ER -